Nightingale Health (HEALTH) H1 2025 earnings summary

Executive summary

• Achieved significant milestones in global adoption, including over 100,000 health checks in Finland and expansion in Japan, Singapore, the U.K., the U.S., and the Middle East, supported by proprietary technology for preventative health.

• Continued execution of a global growth plan with strong financial discipline, aiming to reduce chronic disease burden and healthcare costs.

• Major partnerships formed with Boston Heart Diagnostics and Phenome Health, and a peer-reviewed study published in Nature Communications validating risk prediction models.

Financial highlights

• Revenue for H1 2024-25 was €2.31 million, up 35% year-over-year, with EBITDA improving to -€4.72 million from -€5.34 million and net income narrowing to -€8.2 million from -€8.53 million.

• Net cash position at period end was €58 million, with liquid funds of €60 million and no debt, supporting multiple years of runway.

• Market value at period end was €173.81 million, up from €67.34 million year-over-year.

Outlook and guidance

• Targets for FY 2024-25 include winning large international deals, increasing revenue, and improving adjusted EBITDA.

• Mid-term goals: agreements to analyze 2 million samples annually in Europe and 10 million in the US or Asia, and to achieve positive EBITDA.

• Long-term goal: analyze 100 million samples and generate €500 million in annual revenue.

• Anticipates commercial launches in new markets, including Singapore and the U.S., in the near term.